update welcome our productive company, important and the you to Fourth year XXXX a an to quarter I'm progress. afternoon, Good off was Genomics' on pleased and Call. finish Quarter Earnings Singular to It for
and from key data product and two, one, focus for our will call We focus strategic new areas: the following XXXX; three, XXXX. business and highlights accomplishments on announcements;
traditional these quarter with our Of million shipments split generated quarterly $X.X XX. capital bringing academic arrangements, labs. to and an our X purchases revenue, the GX core We start shipments during total our comprised total December commercial between noncapital X X yet. labs fourth were shipments, of were to GX highest in equal The Let's and and instruments to shipped results. as XX quarter
the our we performance, applications.
We key for our majority flow FX X.X note. launched addition had We and In to on QXX. customers to several users accomplishments revenue to the for commercially Max transitioned to cell per sequencing flow for XXX spatial flow increasing run of than of commercially greater XX% the and to per single the reads widely-run year We to the to improved flow or and recently equal or per of GX, million to sequencing XXX other sequencing, cell the allowing quality the cells, launched reads up Read million get most our GX cell specific kits single increasing reads basis cell billion output reads or patients. billion cell a specifications per activities some run customers to QX application for X.X
our we the projects the cash new innovations burn to impact highest narrowed priorities R&D map, reducing our extending activities road and on while focus Lastly, for and runway. across resources
tissue. scientific and of Turning unveiled new we showcased in-situ is situ in the and At a sequencing discovery. sequencing of high the seq, Florida. include GXX designed streams announcements. pipeline areas Sequencer, to data AGBT data throughput stackable our The in Orlando, the product capabilities, recently platform. the novel unprecedented product and the at Its conference, potential is direct for will We GXX new Spatial Conference near-term novel offer which capabilities of throughput to to spatial has profiling open RNA spatial
single-day of scale, all a readout in H&E combination tissue flexible modalities be technical GXx unprecedented specifications samples at Eli transcripts, and and presented conference, GXX targeted state, will targeted the system. performance week CSO than imaging the of fluorescent to technologies.
At audience, XX the to and readouts area of data enable sharing Glezer, and labs offered more of our offer run will centimeters times, square section. an XXx will GXX the the per existing Co-Founder, same a addition, the system In proteins process standing This with room-only
from to as than an by In of number targets the answer Israel technology have out the GXX Dana-Farber incorporate service GFX have broader tumor such "As been by to spatial such a gene Medical generated content. and panels successful solicit data the at event, in proteins early a year at hosted not of of will presented customizable RNA. or be opportunities understanding as perform XX Initially discuss develop researchers collaborating hundreds will expected CRISPR difficult are samples, of interest the read have to proteins to designed collaborators the spatial kits an internal partners. Catherine a or forward.
We GXX to platforms, to encouraged on also the we on capability projects and a impressive their Center KOL GXX includes available data of readout kits with The and dozens cell excellent [indiscernible] part transcripts, The generated samples of lab Direct-Seq, for who is end of profile potential GXX, GXX we guide from scale direct to and screens funnel data in Content the enable access [ customer will qualified T out of acute The cells a tissues directors The GX and in sample event will and date. larger relationships, with which scientific transcripts, the available has microenvironment the been allowed of RNAs studies."
We are myelogenis directly RNA as be to Cancer Direct-Seq and support this notoriously, in questions throughput as TAP increasingly or potential and released of early sequences. much the GXX GXX and bigger and perform gene the users high-throughput marrow Early to have system available designed sequencing and and beyond."
In program. from community. for Deaconess customer.
Future section. XX impact work have expected of approximately read coming large to XXX programs, will -- of modality are Harvard's customize a the and External collaborators sales receptor situ empower and is conference the leaders fixed high X intend new hotspot later mutations, included and spatial initially envision possible. as on be marketing to working the into the promises regions feedback quality plans our noted, bring larger by very B Institute pathology. us direct ability more bone matures, more panel growing of together feedback and tissue thereafter.
The service and tissue access proteins type, provided well expected panels capability spatial tissue and additional as tremendous to that cancer in addition, will upgrades from to sequencing AGBT. and GXX for the studies have accommodate RNA, support a molecular to XXX the The same the field the stain in to the available addition, the biology from noted, is of adopters release [indiscernible] Direct-Seq for and be powerful previously bring now that leukemia, to that us customers early came and shortly system H&E leads, including will our AML been offer initially in data expanding transcripts, to Wu a external on internal opportunities ], conference. "The for a pipeline be provided within near-term immuno-oncology proteins offer to opportunity platform.
We Beth
to plan GXX the provide quarter. technology in access starting also We services second
our to in and focus Turning XXXX. views strategic
GXX. interest around the by We the are level encouraged of and engagement
this We where setup as access for an is feedback offer we and interest differentiated solutions focus services shift in we multiple focus. Based area and early this the driving especially believe and forward. business intend compelling multiomics sequencing can We GXX, from to compelling on has relates aspects interest novel to the moving our in collaborators, offering. strong economics.
The spatial technology are seeing more early on it with GXX heavily
designed is directly proposition. and any be data be pain the value of value provide other are high addressing categorized asking strength to capabilities customer customers offering novel First, expected unique while proposition modalities is differentiated highly output GXX The points. current for. throughput. This GXX can that into from The to
higher GXX expected significantly both high in XX to to potential instrument. kits margin the XX Second, are be translates current higher a to dollars single The ASPs for business the flow current and pull-through on cell ability GXX the than expected to offer instrument to business. tissue the for on be of higher are samples materially form GX and than throughput consumable and economics attractive. ASPs consumables
to to product and making higher and largely accelerate growth. trade-offs a this dynamics strong labs, the throughput lower and the and market GXX expected the is These this Current that comprised successful fast rapidly. The we cost spatial is space.
We sample. to space bring stages labs uniquely multiomic profiling be and setup and and decisions these are to grow labs. possible. serve Third, reference able GXX product, as for a highly limited. academic The tools need is market be invest as believe market see customers We within early CROs and in in will to growth per current necessary are of
to savings.
To and on our and decision end, We sequencing work was the our XXXX, last spatial also cash cost drive cash the product spending reduced development reduction while to in in will decrease bring still late implement and identify our to customers, need have GXX by our This into actions we earnings market XX%, our supporting recognize manage recently extend savings made more possible. prudently October our We burn to to to taken difficult count additional and cost to reduce our approximately the runway fast as cash resource focus plans continued incremental GX XXXX, discussed resources road the these we focusing this and current head believe as and of actions and our call. map. to heavily
for We additional will on QX XXXX our outlook our color updates provide on earnings and call.
it our to financial results. the over turn through I'll quarter go to details fourth of Dalen Now
